reverse hybrid therapy

Reverse hybrid therapy is a 12-day multi-drug regimen designed for the first-line eradication of *Helicobacter pylori* infection. It is a modification of the standard hybrid therapy, utilizing a 'one-step two-phase' approach. The regimen consists of a proton pump inhibitor (PPI) and amoxicillin administered for the entire 12-day duration, with the addition of clarithromycin and metronidazole specifically during the first 7 days. This sequence is intended to simplify the treatment protocol and potentially improve patient adherence compared to regimens where the antibiotic components change in the middle of the course. Clinical evaluation, including the REHYTRI study conducted by Kaohsiung Veterans General Hospital, has focused on comparing its efficacy and safety profile against standard triple therapy and other established protocols.

Other names

Reverse hybrid regimen